Abstract: Beijing QL Biopharm, a China-based biopharmaceutical company, is looking to raise via a Hong Kong listing. Jefferies and Huatai are the joint sponsors. In this note, we look at the company's one Phase III core product, zovaglutide (ZT002). We also look at the company's pre-IPO investors and management team.
IMEIK TECHNOLOGY DEVELOPMENT
Research on Hong Kong and A+H equity offerings, from the first filing to the aftermarket. Coverage includes pre-IPO early thoughts on the business and valuation, analysis of the final deal terms and cornerstone investors, and updates as new prospectus versions are filed.
Interested in the full report? Get in touch with our team.